scorecardresearch

Tuesday, November 17, 2026

Support our Journalism

Depth, context and analysis

Subscribe
HomeFeatures6-year-old girl dies in experimental gene-editing trial in China. Scientists sacked

6-year-old girl dies in experimental gene-editing trial in China. Scientists sacked

The decision was announced by Shanghai authorities on 13 November, following an investigation conducted in July by ‘Science’ and ‘Retraction Watch’.

Stay updated with ThePrint:

New Delhi: Two scientists who took part in an experimental gene-editing trial that led to the death of a six-year-old girl were dismissed by Chinese authorities after an investigation found serious lapses in safety and ethics alongside hidden funding, Nature reported.

The decision was announced by Shanghai authorities on 13 November, following an investigation conducted in July by Science and Retraction Watch. The investigation unveiled that the girl’s death had not been publicly disclosed by the research team when they published the findings in Nature.

The researchers are Zilong Qiu, a neuroscientist at Shanghai Jiao Tong University School of Medicine, who led the study published in Nature, and Kan Yang, a researcher at Xinhua Hospital, which was affiliated with the University. The duo was dismissed and barred from participating in government-funded research programmes and receiving scientific awards for five years. They were also added to a database for scientists who made severe breaches in ethics.

What happened during the experiment?

The girl, who was pseudonymously identified in the Science-Retraction Watch investigation as Mei, suffered from Snijders Blok-Campeau syndrome, a rare genetic condition that affects brain development. Her parents approached Qiu in 2023, in hopes of returning her to a more normal level of brain development and stopping future complications.

Qiu promised to develop a personalised gene-editing treatment targeting a mutation in the CHD3 gene that was responsible for her condition. The therapy used was one in which the gene-editing components were sent through modified viruses via a spinal injection into the nervous system.

After gaining approval from Xinhua Hospital’s ethics committee, Mei received the experimental treatment on 24 March 2025. Post-operation, she suffered several complications and died seven days later. The cause of death was determined to be thrombotic microangiopathy, a complication involving damage to small blood vessels that damages vital organs such as the kidneys, which the hospital attributed to the gene therapy.

In the investigation, the parents of the child revealed that they contributed approximately $860,000 toward developing the experimental treatment. They were also not given the full extent of the complications that could arise from the operation going wrong.

“We did not realize how unusual and dangerous many of the arrangements were,” her father told the publications.


Also read: Grand India Biennale has a new formula—Purana Qila, PPP, ‘people’s movement’


Safety warnings allegedly overlooked

The official investigation by the authorities found that Qiu’s team failed to promptly share concerning results from experiments involving monkeys with the hospital’s clinical investigators, where the primates developed liver damage after receiving the treatment.

They also found that the hospital approved the treatment without sufficient toxicology data, and their consent documents failed to stress the high risk of death.

“This shouldn’t have gone to trial,” Steven Gray, a gene-therapy researcher at the University of Texas Southwestern Medical Center, told Science and Retraction Watch in July.

Investigators additionally found that researchers received approximately ¥1.06 million in money and gifts from the family, separate from the aforementioned $860,000 in research funding.

While the research team’s February 2026 paper is still available on Nature, there has been retroactive criticism from both the authorities and the experts consulted in the Science-Retraction Watch investigation, with discrepancies being identified in the descriptions of experimental methods and the failures to disclose relevant findings when it came to safety.

Second death raises wider concerns

This is not the first death in China from experimental gene therapy. Shanghai-based HuidaGene Therapeutics published a report on 26 October in Cell that disclosed the death of a young boy in 2025 following treatment for Duchenne muscular dystrophy. Subsequent results outlined in the study showed limited benefits.

The two deaths have now prompted serious questions about the oversight and even need for investigator-initiated trials, which are commonly known as China’s fast-track pathway due to following different regulations from commercially sponsored studies. The deaths could also jeopardise the entire sector of gene therapy.

Shanghai authorities have also ordered corrective measures at the institutions involved and announced additional inspections of research involving emerging biomedical technologies.

“I expect the action to send a big warning to research institutes and hospitals across the country,” Jiayou Shi, a lawyer at the National Research Center for Civil and Commercial Law at Renmin University of China in Beijing, told Nature.

(Edited by Prasanna Bachchhav)

Subscribe to our channels on YouTube, Telegram & WhatsApp

For readers who want the full picture.

You read our articles closely. Subscribe to go further, with exclusive newsletters in your inbox, flagship events hosted by Shekhar Gupta, AMAs with our senior editors, the chance to write under your own byline, and more.

Subscribe to ThePrint →

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular